Evidence map›Paper›PMID 30781409›Full record

ArticlePharmaceuticals (Basel, Switzerland)2019

2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction,

Florian C Maier, Anna Schweifer, Vijaya L Damaraju, Carol E Cass, Gregory D Bowden, Walter Ehrlichmann, Manfred Kneilling, Bernd J Pichler, Friedrich Hammerschmidt, Gerald Reischl

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Recent Advances ofInternational journal of molecular sciences · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Florian C MaierWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany. florian.maier@med.uni-tuebingen.de.
Anna SchweiferFaculty of Chemistry, Institute of Organic Chemistry, University of Vienna, Währingerstraße 38, A-1090 Vienna, Austria. anna.schweifer@univie.ac.at.
Vijaya L DamarajuDepartment of Oncology, University of Alberta, Edmonton, AB T6G 2R7, Canada. vd1@ualberta.ca.
Carol E CassDepartment of Oncology, University of Alberta, Edmonton, AB T6G 2R7, Canada. ccass@ualberta.ca.
Gregory D BowdenWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany. gregory.bowden@med.uni-tuebingen.de.ORCID 0000-0003-2274-6738
Walter EhrlichmannWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany. walter.ehrlichmann@med.uni-tuebingen.de.
Manfred KneillingWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany. manfred.kneilling@med.uni-tuebingen.de.
Bernd J PichlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany. bernd.pichler@med.uni-tuebingen.de.
Friedrich HammerschmidtFaculty of Chemistry, Institute of Organic Chemistry, University of Vienna, Währingerstraße 38, A-1090 Vienna, Austria. friedrich.hammerschmidt@univie.ac.at.
Gerald ReischlWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076 Tübingen, Germany. gerald.reischl@uni-tuebingen.de.
Siemens (Germany) · DEUniversity of Alberta · CAUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The benefits of PET imaging of tumor hypoxia in patient management has been demonstrated in many examples and with various tracers over the last years. Although, the optimal hypoxia imaging agent has yet to be found, 2-nitroimidazole (azomycin) sugar derivatives-mimicking nucleosides-have proven their potential with [

Indexed as

[18F]FMISOazomycin nucleosidesPETsmall animal imagingtumor hypoxia

Identifiers

PMID30781409
PMCPMC6469291
OpenAlexW2911634249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.